Loading...
Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects
Activation of the brain dopamine D1 receptor has attracted attention because of its promising role in neuropsychiatric diseases. Although efforts to develop D1 agonists have been challenging, a positive allosteric modulator (PAM), represents an attractive approach with potential better drug‐like pro...
Na minha lista:
| Udgivet i: | Clin Pharmacol Drug Dev |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8048550/ https://ncbi.nlm.nih.gov/pubmed/33029934 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.874 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|